Page last updated: 2024-11-01

nimodipine and Carcinoma, Small Cell

nimodipine has been researched along with Carcinoma, Small Cell in 1 studies

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cattaneo, MG1
Gullo, M1
Vicentini, LM1

Other Studies

1 other study available for nimodipine and Carcinoma, Small Cell

ArticleYear
Ca2+ and Ca2+ channel antagonists in the control of human small cell lung carcinoma cell proliferation.
    European journal of pharmacology, 1993, Nov-15, Volume: 247, Issue:3

    Topics: Animals; Calcium; Calcium Channel Blockers; Calmodulin; Carcinoma, Small Cell; Cell Division; DNA, N

1993